Nuvectis Pharma, Inc.

NasdaqCM NVCT

Nuvectis Pharma, Inc. Revenue for the Trailing 12 Months (TTM) ending September 30, 2024

Nuvectis Pharma, Inc. Revenue is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Nuvectis Pharma, Inc. Revenue for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 4.25 M, a 106,150.00% change year over year.
Nuvectis Pharma, Inc. Revenue for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 4.00 K.

Key data

Date	Revenue	Gross Profit	Operating Income	EBIT

NasdaqCM: NVCT

Nuvectis Pharma, Inc.

CEO	Mr. Ron Bentsur M.B.A.
IPO Date	Feb. 4, 2022
Location	United States
Headquarters	1 Bridge Plaza
Employees	13
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.

Key trends

Past 5 years